3SBio (HK:1530) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
3SBio Inc.’s subsidiary, Shenyang Sunshine Pharmaceutical, has secured exclusive commercialization rights for clifutinib besylate in Mainland China through a collaboration with Sunshine Lake Pharma. The agreement involves initial and milestone payments, while Sunshine Lake Pharma will manage the drug’s research, development, and production. Investors are advised to remain cautious regarding the potential success of clifutinib’s commercialization.
For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.